Anticancer quinolone yields antileukemia effects and overcomes venetoclax resistance
June 20, 2024
Targeting topoisomerase 2 (TOP2) is crucial in AML, and researchers from Wakunaga Pharmaceutical Co. Ltd. have developed and tested racemic WAC-224, a quinolone TOP2 inhibitor, and (R)-WAC-224 as a potential approach for AML treatment.